Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

56%

5 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 4

4(50.0%)

Phase 2

1(12.5%)

N/A

1(12.5%)

Phase 1

1(12.5%)

Phase 3

1(12.5%)

8Total

Phase 4(4)

Phase 2(1)

N/A(1)

Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01155336Phase 1Terminated

The Effects of Lovaza® in Acute Myocardial Infarction

Role: collaborator

NCT02895672Completed

GLP-1/Basal Insulin Combination Therapy

Role: lead

NCT00915876Not ApplicableCompleted

Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo

Role: collaborator

NCT01312441Phase 4Terminated

Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D

Role: lead

NCT01277497Phase 4Terminated

Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4

Role: lead

NCT01035333Phase 4Completed

A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.

Role: lead

NCT01605864Phase 3Completed

Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia

Role: collaborator

NCT01181882Phase 2Completed

Fish Oil and Aspirin With Type 2 Diabetes

Role: collaborator

NCT00939952Phase 4Completed

Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis

Role: lead

All 9 trials loaded